These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15742461)

  • 21. Transcending conventional therapies: the role of biologic and other novel therapies.
    Sandborn WJ
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S9-16. PubMed ID: 11380043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.
    van Deventer SJ
    Gastroenterology; 2001 Nov; 121(5):1242-6. PubMed ID: 11677219
    [No Abstract]   [Full Text] [Related]  

  • 24. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
    Briot K; Gossec L; Kolta S; Dougados M; Roux C
    J Rheumatol; 2008 May; 35(5):855-61. PubMed ID: 18381782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF inhibition in SLE: where do we stand?
    Aringer M; Smolen JS
    Lupus; 2009 Jan; 18(1):5-8. PubMed ID: 19074162
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
    Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of infliximab treatment on rheumatoid synovial tissue.
    Tak PP
    J Rheumatol Suppl; 2005 Mar; 74():31-4. PubMed ID: 15742462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures.
    Agnholt J; Dahlerup JF; Kaltoft K
    Cytokine; 2003 Aug; 23(3):76-85. PubMed ID: 12906870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.
    Ostergaard M; Unkerskov J; Linde L; Krogh NS; Ravn T; Ringsdal VS; Petri A; Andersen LS; Tarp U; Hansen A; Hjardem E; Hetland ML
    Scand J Rheumatol; 2007; 36(2):151-4. PubMed ID: 17476624
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effects of TNF antagonists on immune and neuroendocrine system].
    Valesini G; Cutolo M
    Reumatismo; 2005; 57(4 Suppl):3-7. PubMed ID: 16385349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    Sands BE
    Rev Gastroenterol Disord; 2004; 4 Suppl 3():S10-7. PubMed ID: 15580148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 40. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.